KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.

  • Biomarin Pharmaceutical's Enterprise Value fell 5883.16% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 5883.16%. This contributed to the annual value of -$1.1 billion for FY2024, which is 595.04% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Enterprise Value stood at -$1.5 billion for Q3 2025, which was down 5883.16% from -$1.4 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Enterprise Value ranged from a high of -$930.4 million in Q3 2024 and a low of -$1.5 billion during Q3 2025
  • Over the past 5 years, Biomarin Pharmaceutical's median Enterprise Value value was -$1.1 billion (recorded in 2023), while the average stood at -$1.2 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first soared by 2830.61% in 2021, then plummeted by 5883.16% in 2025.
  • Biomarin Pharmaceutical's Enterprise Value (Quarter) stood at -$1.0 billion in 2021, then decreased by 27.39% to -$1.3 billion in 2022, then rose by 16.86% to -$1.1 billion in 2023, then fell by 5.95% to -$1.1 billion in 2024, then decreased by 29.9% to -$1.5 billion in 2025.
  • Its last three reported values are -$1.5 billion in Q3 2025, -$1.4 billion for Q2 2025, and -$1.3 billion during Q1 2025.